Mizuho raised the firm’s price target on Axsome Therapeutics (AXSM) to $202 from $200 and keeps an Outperform rating on the shares. The company reported strong Q3 results with sales beats for both Auvelity and Sunosi, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics management to meet with Truist
- Axsome Therapeutics’ Earnings Call Highlights Growth and Challenges
- Axsome Therapeutics price target raised to $198 from $189 at RBC Capital
- Axsome Therapeutics price target raised to $185 from $180 at H.C. Wainwright
- Axsome Therapeutics price target raised to $196 from $194 at Morgan Stanley